Tag Archives: William M Mitchell

Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS

Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by David R Strayer, Diane Young, William M Mitchell in  PLoS ONE 15(10): e0240403, Oct 29 2020 [doi.org/10.1371/journal.pone.0240403]   Research … Continue reading

Posted in News | Tagged , , , , , , , | Comments Off on Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS